Nanomedicine: The Medicine of Tomorrow

Chapter
Part of the NanoScience and Technology book series (NANO)

Abstract

Nowadays nanotechnology has become a technological field with great potential since it can be applied in almost every aspect of modern life. One of the sectors where nanotechnology is expected to play a vital role is the field of medical science. The interaction of nanotechnology with medicine gave birth to a completely new scientific field called nanomedicine. Nanomedicine is a field that aims to use the nanotechnology tools and principles in order to improve human health in every possible way. Nanotechnology provides monitoring tools and technology platforms that can be used in terms of detection, diagnostic, bioanalysis and imaging. New nanoscale drug-delivery systems are constantly designed with different morphological and chemical characteristics and unique specificity against tumours, offering a less harmful approach alternative to chemo- and radiotherapies. Furthermore, nanotechnology has led to great breakthroughs in the field of tissue engineering, making the replacement of damaged tissues and organs a much feasible procedure. The thorough analysis of bio and non-bio interactions achieved by versatile nanotools is essential for the design and development of highly performed medical implants. The continuous revolution in nanotechnology will result in the fabrication of nanostructures with properties and functionalities that can benefit patient’s physiology faster and more effectively than conventional medical procedures and protocols. The number of nanoscale therapeutical products is rapidly growing since more and more nanomedical designs are reaching the global market. However the nanotoxic impact that these designs can have on human health is an era that requires still more investigation. The development of specific guidance documents at a European level for the safety evaluation of nanotechnology products in medicine is strongly recommended and the need for further research in nanotoxicology is identified. Ethical and moral concerns also need to be addressed in parallel with the new developments.

Keywords

Solid Lipid Nanoparticles Protein Chip Cadmium Selenide Toxicological Risk Amorphous Carbon Thin Film 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    K. Park, “Nanotechnology: What it can do for drug delivery”, perspective, J. Contr. Release 120, 1–3 (2007)CrossRefGoogle Scholar
  2. 2.
    W.H. de Jong, B. Roszek, R.E. Geertsma, “Nanotechnology in medical applications: possible risks for human health”, RIVM report 265001002, 2005. RIVM, National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 2005Google Scholar
  3. 3.
    B. Roszek, W.H. de Jong, R.E. Geertsma, “Nanotechnology for medical applications: state-of-the-art in materials and devices”, RIVM report 265001001, 2005. RIVM, National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 2005Google Scholar
  4. 4.
  5. 5.
    M. Foldvari, M. Bagonluri, “Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues”, Nanomed.: Nanotechnol. Biol. Med. 4(3), 183–200 (2008)Google Scholar
  6. 6.
    H.S. Mansur, “Quantum dots and nanocomposites”, Wiley Interdiscipl. Rev.: Nanomed. Nanobiotechnol. (2)2, 113–129 (2010)Google Scholar
  7. 7.
    L.D. True, X. Gao, “Quantum dots for molecular pathology: Their time has arrived”, J. Mol. Diagnostics 9(1), 7–11 (2007)CrossRefGoogle Scholar
  8. 8.
    S. Svenson, “Dendrimers as versatile platform in drug delivery applications”, Eur. J. Pharm. Biopharm. 71(3), 445–462 (2009)CrossRefGoogle Scholar
  9. 9.
    B. Haley, E. Frenkel, “Nanoparticles for drug delivery in cancer treatment”, Urol. Oncol.: Semin. Original Investig. 26(1), 57–64 (2008)Google Scholar
  10. 10.
    A. Shahverdi, A. Fakhimi, H. Shahverdi, S. Minaian, “Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli”, Nanomed.: Nanotechnol. Biol. Med. 3(2) 168–171 (2007)Google Scholar
  11. 11.
    G.A. Silva, “Introduction to nanotechnology and its applications to medicine”, Surg. Neurol. 61, 216 (2004)CrossRefGoogle Scholar
  12. 12.
    D. Khatayevich, M. Gungormus, H. Yazici, C. So, S. Cetinel, M. Hong, A. Jen, C. Tamerler, M. Sarikaya, “Biofunctionalization of materials for implants using engineered peptides”, Acta Biomater. 6(12), 4634–4641 (2010)CrossRefGoogle Scholar
  13. 13.
  14. 14.
    S. Logothetidis, M. Gioti, S. Lousinian, S. Fotiadou, “Haemocompatibility studies on carbon-based thin films by ellipsometry”, Thin Solid Films 482(1–2), 126 (2004)Google Scholar
  15. 15.
    H. Elwing, “Protein absorption and ellipsometry in biomaterial research”, Biomaterials 19, 397 (1998)CrossRefGoogle Scholar
  16. 16.
    E. Garcia-Caurel, J. Nguyen, L. Schwartz, B. Drévillon, “Application of FTIR ellipsometry to detect and classify microorganisms”, Thin Solid Films 455, 722 (2004).ADSCrossRefGoogle Scholar
  17. 17.
    E. Garcia-Caurel, J. Nguyen, L. Schwartz, B. Drévillon, “Moving ellipsometry from materials to medicine”, III–Vs Rev. 17, 4 (2004)Google Scholar
  18. 18.
    H. Arwin, “Application of ellipsometry techniques to biological materials”, Thin Solid Films 519(9), 2589–2592, (2011)ADSCrossRefGoogle Scholar
  19. 19.
    Nanomedicine, An ESF – European Medical Research Councils (EMRC) Forward Look report 2005, (http://www.nanoforum.org)
  20. 20.
    K. Mitsakakis, S. Lousinian, S. Logothetidis, “Early stages of human plasma proteins adsorption probed by atomic force microscope”, Biomol. Eng. 24(1), 119–124, (2007)CrossRefGoogle Scholar
  21. 21.
  22. 22.
  23. 23.
    C. Wei, “Highlights of the first annual meeting of the American Academy of Nanomedicine”, Nanomed.: Nanotechnol. Biol. Med. 1, 351 (2005)Google Scholar
  24. 24.
    J. Maienschein, “Regenerative medicine’s historical roots in regeneration, transplantation and translation”, Dev. Biol. (Article in Press), (2010).Google Scholar
  25. 25.
    J. Vacanti, “Tissue engineering and regenerative medicine: from first principles to state of the art”, J. Pediatr. Surg. 45, 291–294 (2010)CrossRefGoogle Scholar
  26. 26.
    E. Anitua, M. Sanchez, G. Orive, “Potential of endogenous regenerative technology for in situ regenerative medicine”, Adv. Drug Deliv. Rev. 62(7–8), 741–752 (2010)CrossRefGoogle Scholar
  27. 27.
    D.L. Borjesson, J.F. Peroni, “The regenerative medicine laboratory: facilitating stem cell therapy for equine disease”, Clin. Lab. Med. 31(1), 109–123, (2011)CrossRefGoogle Scholar
  28. 28.
    D. Sheyn, O. Mizrahi, S. Benjamin, Z. Gazit, G. Pelled, D. Gazit, “Genetically modified cells in regenerative medicine and tissue engineering”, Adv. Drug Deliv. Rev. 62(7–8), 683–698, (2010)CrossRefGoogle Scholar
  29. 29.
    I. Martin, D. Wendt, M. Heberer, “The role of bioreactors in tissue engineering”, Trends Biotechnol. 22(2), 80–86, (2004)CrossRefGoogle Scholar
  30. 30.
    Y. Martin, P. Vermette, “Bioreactors for tissue mass culture: Design, characterization and recent advances”, Biomaterials 26, 7481–7503, (2005)CrossRefGoogle Scholar
  31. 31.
    A.B. Yeatts, J.P. Fisher, “Bone tissue engineering bioreactors: Dynamic culture and the influence of shear stress”, Bone 48, 171–181, (2011)CrossRefGoogle Scholar
  32. 32.
    C. Van Blitterswijk, P. Thompsen, J. Hubbell, R. Cancedda, A. Lindahl, J.D. De Bruijn, J. Sohier, D.F. Williams, Tissue Engineering, Chapter 16: Bioreactors for tissue engineering, 483–506, (Academic, New York, 2008).Google Scholar
  33. 33.
    A. Robert, J.D. Freitas, “What is nanomedicine?”, Nanomed.: Nanotechnol. Biol. Med. 1(2) (2005)Google Scholar
  34. 34.
    R.F. Service, “Nanotechnology takes aim at cancer”, Science 310(5751), 1132 (2005).Google Scholar
  35. 35.
    M.M. Stevens, J.H. George, “Exploring and engineering the cell surface interface”, Science 310(5751), 1135 (2005)Google Scholar
  36. 36.
    V.P. Zharov, J.W. Kim, et al.,, “Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy”, Nanomed.: Nanotechnol. Bio. Med. 1, 326 (2005)Google Scholar
  37. 37.
    G. Korpanty, et al., “Targeting of VEGF-mediated angiogenesis to rat myocardium using ultrasonic destruction of microbubbles”, Gene Ther. 12, 1305 (2005)CrossRefGoogle Scholar
  38. 38.
    A.C. Morton, D. Crossman, J. Gunn, (2004) The influence of physical stent parameters upon restenosis, Pathologie Biologie 52, 196–205 (2004)CrossRefGoogle Scholar
  39. 39.
    X. Chen, K. Fujise, “Restenosis: Emerging molecular targets. Going beyond drug-eluting stents”, Drug Discov. Today: Dis. Mech./Cardiovasc. Dis. 2(I) (2005)Google Scholar
  40. 40.
  41. 41.
    C. Zandonella, “The tiny toolkit”, Nature 423, 10–12 (2003)ADSCrossRefGoogle Scholar
  42. 42.
    I. Brigger, C. Dubernet, P. Couvreur, “Nanoparticles in cancer therapy and diagnosis”, Adv. Drug Deliv. Rev. 54, 631–651 (2002)CrossRefGoogle Scholar
  43. 43.
    T.K. Jain, S.P. Foy, B. Erokwu, S. Dimitrijevic, C.A. Flask, V. Labhasetwar, “Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice”, Biomaterials, 30(35), 6748–6756, (2009)CrossRefGoogle Scholar
  44. 44.
    D.E. Sosnovik, M. Nahrendorf, R. Weissleder, “Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications”, Basic Res. Cardiol. 103(2), 122–130, (2008)CrossRefGoogle Scholar
  45. 45.
    B. Bonnemain, “Superparamagnetic agents in magnetic resonance imaging: physiochemical characteristics and clinical applications – a review”, J. Drug Target 6, 167–174 (1998)CrossRefGoogle Scholar
  46. 46.
    T. Neuberger, B. Schopf, H. Hofmann, M. Hofmann, B. Von Rechenberg, “Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system”, J. Magn. Magn. Mater. 293(1) 483–496 (2005)ADSCrossRefGoogle Scholar
  47. 47.
    E.S. Kawasaki, T.A. Player, “Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer”, Nanomed.: Nanotechnol. Biol. Med. 1, 101–109 (2005)Google Scholar
  48. 48.
    C. Tachung, P.E. Yih, C. Wie, “Nanomedicine in cancer treatment”, Nanomed.: Nanotechnol. Biol. Med. 1, 191–92 (2005)Google Scholar
  49. 49.
    V. Zharov, V. Galitovsky, M. Viegas, “Photothermal detection of local thermal effects during selective nanophotothermolysis”, Appl. Phys. Lett. 83, 4897 (2003)ADSCrossRefGoogle Scholar
  50. 50.
    V.P. Zharov, V. Galitovsly, M. Viegas, “Photothermal guidance of selective photothermolysis with nanoparticles”, Proc. SPIE 5319, 291 (2004)ADSCrossRefGoogle Scholar
  51. 51.
    D.P. O’Neal, L.R. Hirsch, N.J. Halas, J.D. Payne, J.L. West, “Photothermal tumor ablation in mice using near infrared-absorbing nanoparticles”, Cancer Lett. 209, 171 (2004)CrossRefGoogle Scholar
  52. 52.
    J. Bradbury, “Nanoshell destruction of inoperable tumors”, Lancet Oncol. 4, 711 (2003)CrossRefGoogle Scholar
  53. 53.
    X. Huang, M.A. El-Sayed, “Gold nanoparticles: Optical properties and implementations in cancer diagnosis and photothermal therapy”, J. Adv. Res. 1(1), 13–28, (2010)CrossRefGoogle Scholar
  54. 54.
  55. 55.
    Willems & van den Wildenberg, NanoRoadMap Project, October 2004, (http://www.nanoroadmap.it/sectoral%20reports/sect%20report%20health.PDF)
  56. 56.
    A. Hett et al., “Nanotechnology: Small matter, many unknowns”, Swiss Reinsurance Company (2004) (http://www.swissre.com/INTERNET/pwswpspr.nsf/fmBookMarkFrameSet?ReadForm&BM=./vwAllbyIDKeyLu/ulur-5yaffs?OpenDocument)
  57. 57.
    Y. Pan, A. Leifert, D. Ruau, S. Neuss, J. Bornemann, G. Schmid, W. Brandau, U. Simon, W. Jahnen-Deschent, “Gold nanoparticles of diameter 1,4 nm trigger necrosis by oxidative stress and mitochondrial damage”, Small 5(18), 2067–2076, (2009)CrossRefGoogle Scholar
  58. 58.
    N. Singh, B. Manshian, G. Jenkins, S. Griffiths, P. Williams, T. Maffeis, C. Wright, S. Doak, “NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials”, Biomaterials 30, 3891–3914, (2009)CrossRefGoogle Scholar
  59. 59.
    M.C. Roco, “Nanotechnology: convergence with modern biology and medicine”, Curr. Opin. Biotechnol. 14, 337 (2003)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Physics DepartmentAristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations